These Undervalued Cannabis Stocks Could Go Parabolic in 2022 January 06, 2022 - Baystreet.ca The global cannabis boom is just getting started. In fact, according to Prohibition Partners, global sales of CBD, medical, and recreational cannabis sales topped $37.4 billion in 2021, and could be on course to see $102 billion in sales by 2026. “Adult-use markets in the US and Canada remain the most important regions in the world for cannabis sales, but international markets including Germany, Israel and Australia will develop considerably over the next five years,” they noted. “As of late 2021 only Uruguay, Canada and a handful of states in the US have fully legalized cannabis for adult-use, but these will be joined by several international markets soon. Mexico and Israel are primed for full legalization of adult-use cannabis in 2022, while the Netherlands and Switzerland are preparing for their legal pilot trials.” Even better, analysts at Vantage Market Research say the global market could run to $128.92 billion by 2028, which could be substantially beneficial for Xebra Brands (CSE:XBRA)(OTC:XBRAF), Aurora Cannabis (NASDAQ:ACB)(TSX:ACB), Canopy Growth (TSX:WEED) (NASDAQ:CGC), Tilray Inc. (NASDAQ:TLRY)(TSX:TLRY), and Aleafia Health Inc. (TSX:AH)(OTC:ALEAF). Look at Xebra Brands’ (CSE:XBRA)(OTC:XBRAF), For Example Xebra Brands Ltd. a cannabis company just announced that it has commenced formal cannabis cultivation in the Netherlands, including THC varietals. As 1 of only 5 companies to be selected by the Dutch government to participate in trial medicinal cannabis cultivation, Xebra is endeavoring to be awarded 1 of 2 licenses, with a contract for up to 6 years, providing for revenues of up to US$79 million (€70.5 million), to co-supply all pharma-grade cannabis to be sold in the Netherlands. Cultivation in the Netherlands is conducted in Xebra’s indoor facility. Xebra’s specific genetic varieties are characterized by high production, compact flowers of excellent quality and fine tasting terpene profiles, with a growth cycle of 12-16 weeks. Xebra’s Director of Operations in the Netherlands, Harry von Duijne, is an experienced cannabis horticulture expert with more than two decades of practicing horticulture. He had a leading role at Bedrocan NL® from 2014 and 2017, where he was responsible for managing every aspect of operations of a state-of-the-art cannabis facility, from construction through cultivation and processing, quality management, and GMP certification. Bedrocan® produces medicinal-grade cannabis under contract for the Dutch Ministry of Health as the only licensed producer in the Netherlands, and for many years was the only licensed producer in all of Europe. Other related developments from around the markets include: Aurora Cannabis, the Canadian company defining the future of cannabinoids worldwide, announced the delivery of a cannabis shipment worth approximately C$10 million - the company's largest ever shipment to Israel, and what is believed to be the largest export of medical Cannabis into the Israeli market. Delivered in December, the shipment will be recognized as revenue in Aurora's FY22 Q2 period. The sale builds on the Company's growing presence in Israel, a key market as Aurora continues to strengthen its international medical business. As the leading Canadian licensed producer (LP) in global medical cannabis by revenue, Aurora has strategically focused on international expansion to bolster its diversified business portfolio. The Company also recently entered into a joint venture in The Netherlands to participate in the Controlled Cannabis Supply Chain Experiment, an adult-use pilot program. Canopy Growth announced the release of its Environmental, Social, and Governance (ESG) Report for calendar year 2020, as well as qualitative details on some key activities that occurred in 2021. The Report recognizes Canopy’s current progress and describes its priorities and approach to ESG as part of its long-term path towards responsible and sustainable growth. “As the cannabis industry becomes more established, we recognize the role we must play to ensure that progress is achieved responsibly and sustainably,” said David Klein, CEO Canopy Growth. “We are committed to realizing our vision of unleashing the power of cannabis to improve lives and our inaugural ESG report is the next step in our leadership journey, creating accountability for ourselves, and the cannabis industry.” Tilray Inc. announced that the Company will release financial results for its second quarter fiscal 2022 ended November 30, 2021 before financial markets open on January 10, 2022. Tilray executives will host a conference call and live audio webcast to discuss these results Call-in Number: (877) 407-0792 from Canada and the U.S. or (201) 689-8263 from international locations. Please dial in at least 10 minutes prior to the start time. A telephone replay will be available approximately two hours after the call concludes through January 26, 2022. To access the recording dial (844)-512-2921 and use the passcode 13725661. Aleafia Health Inc. reported its financial results for the three and nine months ended September 30th, 2021. The Company’s 2021 third quarter unaudited, consolidated financial statements and management discussion and analysis will be available in the Investors section of the Company’s website at aleafiahealth.com and will be filed on SEDAR and available at sedar.com. “Our momentum in the adult-use cannabis sector has continued with our strongest quarter to date by a significant margin,” said Aleafia Health CEO Geoffrey Benic. “Consumer demand for our portfolio has been clearly demonstrated as we now begin to capture meaningful market share, entering the top 10 nationally in the pre-roll, edible, and oils categories. Most importantly, we’ve realized a five-fold sequential increase in dried flower market share during the quarter, in a category that is both Canada’s largest and one that leverages our low-cost cultivation advantage. Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Xebra Brands has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of Xebra Brands. Click here for disclaimer. Contact Information: 2818047972 ty@LifeWaterMedia.com
These Undervalued Cannabis Stocks Could Go Parabolic in 2022 January 06, 2022 - Baystreet.ca The global cannabis boom is just getting started. In fact, according to Prohibition Partners, global sales of CBD, medical, and recreational cannabis sales topped $37.4 billion in 2021, and could be on course to see $102 billion in sales by 2026. “Adult-use markets in the US and Canada remain the most important regions in the world for cannabis sales, but international markets including Germany, Israel and Australia will develop considerably over the next five years,” they noted. “As of late 2021 only Uruguay, Canada and a handful of states in the US have fully legalized cannabis for adult-use, but these will be joined by several international markets soon. Mexico and Israel are primed for full legalization of adult-use cannabis in 2022, while the Netherlands and Switzerland are preparing for their legal pilot trials.” Even better, analysts at Vantage Market Research say the global market could run to $128.92 billion by 2028, which could be substantially beneficial for Xebra Brands (CSE:XBRA)(OTC:XBRAF), Aurora Cannabis (NASDAQ:ACB)(TSX:ACB), Canopy Growth (TSX:WEED) (NASDAQ:CGC), Tilray Inc. (NASDAQ:TLRY)(TSX:TLRY), and Aleafia Health Inc. (TSX:AH)(OTC:ALEAF). Look at Xebra Brands’ (CSE:XBRA)(OTC:XBRAF), For Example Xebra Brands Ltd. a cannabis company just announced that it has commenced formal cannabis cultivation in the Netherlands, including THC varietals. As 1 of only 5 companies to be selected by the Dutch government to participate in trial medicinal cannabis cultivation, Xebra is endeavoring to be awarded 1 of 2 licenses, with a contract for up to 6 years, providing for revenues of up to US$79 million (€70.5 million), to co-supply all pharma-grade cannabis to be sold in the Netherlands. Cultivation in the Netherlands is conducted in Xebra’s indoor facility. Xebra’s specific genetic varieties are characterized by high production, compact flowers of excellent quality and fine tasting terpene profiles, with a growth cycle of 12-16 weeks. Xebra’s Director of Operations in the Netherlands, Harry von Duijne, is an experienced cannabis horticulture expert with more than two decades of practicing horticulture. He had a leading role at Bedrocan NL® from 2014 and 2017, where he was responsible for managing every aspect of operations of a state-of-the-art cannabis facility, from construction through cultivation and processing, quality management, and GMP certification. Bedrocan® produces medicinal-grade cannabis under contract for the Dutch Ministry of Health as the only licensed producer in the Netherlands, and for many years was the only licensed producer in all of Europe. Other related developments from around the markets include: Aurora Cannabis, the Canadian company defining the future of cannabinoids worldwide, announced the delivery of a cannabis shipment worth approximately C$10 million - the company's largest ever shipment to Israel, and what is believed to be the largest export of medical Cannabis into the Israeli market. Delivered in December, the shipment will be recognized as revenue in Aurora's FY22 Q2 period. The sale builds on the Company's growing presence in Israel, a key market as Aurora continues to strengthen its international medical business. As the leading Canadian licensed producer (LP) in global medical cannabis by revenue, Aurora has strategically focused on international expansion to bolster its diversified business portfolio. The Company also recently entered into a joint venture in The Netherlands to participate in the Controlled Cannabis Supply Chain Experiment, an adult-use pilot program. Canopy Growth announced the release of its Environmental, Social, and Governance (ESG) Report for calendar year 2020, as well as qualitative details on some key activities that occurred in 2021. The Report recognizes Canopy’s current progress and describes its priorities and approach to ESG as part of its long-term path towards responsible and sustainable growth. “As the cannabis industry becomes more established, we recognize the role we must play to ensure that progress is achieved responsibly and sustainably,” said David Klein, CEO Canopy Growth. “We are committed to realizing our vision of unleashing the power of cannabis to improve lives and our inaugural ESG report is the next step in our leadership journey, creating accountability for ourselves, and the cannabis industry.” Tilray Inc. announced that the Company will release financial results for its second quarter fiscal 2022 ended November 30, 2021 before financial markets open on January 10, 2022. Tilray executives will host a conference call and live audio webcast to discuss these results Call-in Number: (877) 407-0792 from Canada and the U.S. or (201) 689-8263 from international locations. Please dial in at least 10 minutes prior to the start time. A telephone replay will be available approximately two hours after the call concludes through January 26, 2022. To access the recording dial (844)-512-2921 and use the passcode 13725661. Aleafia Health Inc. reported its financial results for the three and nine months ended September 30th, 2021. The Company’s 2021 third quarter unaudited, consolidated financial statements and management discussion and analysis will be available in the Investors section of the Company’s website at aleafiahealth.com and will be filed on SEDAR and available at sedar.com. “Our momentum in the adult-use cannabis sector has continued with our strongest quarter to date by a significant margin,” said Aleafia Health CEO Geoffrey Benic. “Consumer demand for our portfolio has been clearly demonstrated as we now begin to capture meaningful market share, entering the top 10 nationally in the pre-roll, edible, and oils categories. Most importantly, we’ve realized a five-fold sequential increase in dried flower market share during the quarter, in a category that is both Canada’s largest and one that leverages our low-cost cultivation advantage. Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Xebra Brands has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of Xebra Brands. Click here for disclaimer. Contact Information: 2818047972 ty@LifeWaterMedia.com